Articles On Pharmaxis (ASX:PXS)

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Themes of the week We’re coming...

The Australian Government matched funding under the Biomedical Translation Bridge program will allow the company to take amine oxidase inhibitor PXS-4699 through to the start of human clinical trials.

A quick wrap of the ASX’s key winners and losers on Thursday, August 20. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 553 stocks rose, 765 declined and...

Sydney-based Pharmaxis (ASX:PXS) says the US FDA has completed a safety review of the company’s Investigational New Drug application for its pan-LOX inhibitor PXS-5505 and given it permission to proceed with a new clinical trial....

The Food and Drug Administration has completed a safety review of the company’s Investigational New Drug application for the pan-LOX inhibitor PXS-5505.

A timeline agreed with US licensee Chiesi Farmaceutici will see the US$7 million payment made upon US approval of Bronchitol by the Food and Drug Administration who have advised a Goal Action Date of November 1, 2020.

The Pharmaxis Ltd (ASX: PXS) share price has surged 8.24% today at the time of writing, after the pharmaceutical research company announced a US$7 million payment milestone had been brought forward. The payment will now be made on the dat...

The application to the US Food and Drug Administration (FDA) is for a planned phase 1/2 study of PXS-5505 which is expected to start later this year.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The market...

Sydney-based biopharmaceutical company Pharmaxis (ASX:PXS) has announced the US FDA has granted orphan‐drug designation for its oral pan LOX inhibitor PXS‐5505 for the treatment of myelofibrosis.

Orphan designation qualifies the sponsor of the drug for various development incentives such as reduced regulatory fees and extended periods of market exclusivity.

Resubmission follows Chiesi Group’s successful completion of a supplemental human factor study which was the most significant body of additional data required by the FDA.

Sydney-based biopharmaceutical company Pharmaxis has announced the appointment of experienced US-based industry executive Dr Neil Graham to its board of directors.

The new US-based non-executive director is an experienced senior global pharma and biotech executive.

The company completed both its phase 1b trial of its systemic pan‐LOX inhibitor and a further phase 1 dosing study of its LOXL2 inhibitor in March.

A pre-clinical program, regulatory advice and opinion from leading clinicians supports progression into phase 2 study of the rare bone cancer with high unmet need and significant market opportunity.

Cancer hopeful Pharmaxis (ASX: PXS) is moving ahead with a treatment for a rare bone cancer called myelofibrosis, after a phase 1b study showed it didn’t have any negative effects on the 16 healthy volunteers who took it. The company is set...

Australian company Pharmaxis (ASX:PXS) says positive results from phase 1b and long-term toxicity studies of its oral anti‐fibrotic LOX inhibitor PXS‐5505 mean it is now progressing to a phase 2 study for the treatment of the rare b...

The company is adding to the LOXL2 data package with a small but important phase 1 study investigating the effect of food and different dosing regimens.

Shares overcame an early wobble to resume their push towards all-time highs. The ASX 200 dipped 14 points mid-morning before advancing to a mid-session gain of eight points or 0.1 per cent at 6855. The advance brought the index within a...

Pharmaxis’ (PXS) German partner has dumped its nonalcoholic steatohepatitis drug The company bought the drug from Pharmaxis in 2015 but said today it will no longer be developing the treatment This comes as a blow to Pharmaxis who was set...

Boehringer Ingelheim diabetic eye study continues after discontinuation of NASH trial.

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Pharmaxis shares are in free-fall in pre-open trading, after a German pharmaceutical giant declined to take one of its drugs forward after finding it had a bad interaction with another drug. Boehringer Ingelheim has decided not to develop a...

Whether a day trader or a long-term investor, we often examine research released by industry experts, brokers and analysts with a view to uncovering the next big thing. The more complex the sector, the more we are likely to rely on informat...

Pharmaxis (ASX:PXS) has some big news from its German partner, but won’t yet say whether it’s good or bad. The company has been waiting on pharmaceutical major Boehringer Ingelheim to decide whether it wants to go ahead and further develop...

Air pollution is a growing problem that in recent days has reached our own backyard. Because of the bushfires in surrounding areas, Sydney’s air has been ranked the ninth worst in the world. It’s not the first time in history it’s happened...

As the year winds down and AGM season concludes brokers have been busy filling their Christmas stockings with stock picks they think will be winners. Here are five predictions made in the last week that stood out: 1. Navarre Minerals (ASX:N...

No other sector among ASX small caps has had a better year than the health sector. On average small caps in this industry (small caps with a Global Industry Classification Standard code of 35) have gained 27 per cent. By comparison, mining...

Stockhead’s resident Health and Biotech expert Tim Boreham is coming to you live from the 2019 AusBiotech event in Melbourne. In this episode Tim chats with CEO and MD of Dimerix, Nina Webster, and CEO of Pharmaxis, Gary Phillips. Dimerix...

Drug Development Process The drug development process starts from drug discovery and ends at the launch of the new pharmaceutical product in the market. The process includes drug discovery and development, preclinical trials, clinical trial...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

"We are currently pursuing a number of different partnering options to enable this drug to commence phase 2 efficacy studies in patients with IPF or NASH,” said Pharmaxis CEO Gary Phillips.

The company’s CEO Gary Phillips has presented during the 2019 AusBiotech Conference in Melbourne.

Sydney-based Pharmaxis (ASX:PXS) has provided an update on the FDA's consideration of its cystic fibrosis therapy BRONCHITOL (mannitol).

The FDA review of the Bronchitol NDA (new drug application) is expected to be completed in the second quarter of 2020.

This drug is targeting the treatment of cancers including myelofibrosis and pancreatic cancer.

Health stocks are reckoned amid those that can rapidly grow from a single line of product with small market capitalisation to a company worth over billions. Regarded as one of the most exciting sectors of the stock market, health stocks hol...

The Board of advanced Australian lithium developer Core Lithium (ASX: CXO) has announced the appointment of Malcolm McComas as a non-executive director, effective immediately. Mr McComas joins the Board as Core strengthens the organisation...

Receipt of this incentive adds to the company’s cash funds, which were $31 million at 30 June 2019.

“The R&D tax incentive provides significant leverage to the Pharmaxis research team’s development of new drugs for inflammation and fibrotic diseases," said CEO Gary Phillips.

Pharmaxis was ranked 38 out of the 100 companies named as innovators in the small to medium- sized enterprises category.

Pharmaxis, one of last year’s biggest small cap reporting season winners, has tumbled 412 per cent into the red as its fortunes fluctuate on the anti-inflammatory drug it sold to German pharma giant Boehringer Ingelheim four years ago. Afte...

Stockhead’s Top 10 at 10 highlights the best (and the worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (e...

On Stockhead today, what small fries can learn from big health caps, an expert’s view of where crypto is headed, and Barry FitzGerald gets his heavy metal on.   But first, here’s what you need to know. The day ahead Australian labour market...